CN1321134C - Hetergeneous product of bio-active protein and its preparing process - Google Patents

Abstract

The present invention provides a non-uniform product of bioactivity protein, which comprises G-CSF(15% to 85%) of the chemical modification of polyethyleneglycol, G-CSF, or the analog (85% to 15%), wherein the molecular weight of the polyethyleneglycol is 4000-50000 daltons. The product has the advantages of rapid effect, long durable function time, and stable water solution, and can be combined with an additive agent accepted on pharmacy to be medicine composition. The present invention also provides a method for preparing the non-uniform product of the bioactivity protein, and enables the G-CSF and polyethyleneglycol molecules to generate coupling reaction under alkaline environment; the present invention has the advantage of simple production process, adopts one-step chemical reaction, saves a separation step of a single pure product, reduces cost, and is beneficial to large-scale industrial production.

Description

A kind of Hetergeneous product of bio-active protein and preparation method thereof

Technical field

The present invention relates to the protein modification field, relate to the field of the amino-acid residue and the water soluble polymerizer covalent modification of granulocyte colony-stimulating factor (G-CSF) particularly.

Background technology

Granulocyte colony-stimulating factor (G-CSF) is a kind of cytokine that promotes the hemocyte growth, and it can promote granulocytic growth hematopoiesis, induces its differentiation, propagation and ripe.The recovery that reduces for neutrophil leucocyte has obvious facilitation.As a kind of baiyao that rises, G-CSF at home and abroad is extensive use of clinically.But because its high clearance rate in vivo, patient must injection every day once keep effective blood concentration.By the PEG modifying protein, then can solve this disadvantage (Mumtaz S, BachhawatBK, Indian J Biochem BiopHys 1991 Oct-Dec of genetically engineered drug; 28 (5-6): 346-51).(EP0,335,423 are also delivered in the research of relevant this respect successively in various countries' patent; EP0,401,384; USP4,904,584; USP5,773,581; USP5,824,784).Yet, because the expensive property of this technology and the uncertainty of reaction site bring no small difficulty for the industrialization of PEG modifying protein.And the protein biological activity of PEGization decreases; Onset is slower in vivo; And because of clearance rate is low in vivo, so repeatedly use easily to the kidney toxigenicity.

Summary of the invention

In order to overcome the above-mentioned shortcoming of PEG modifying protein industrialization, the present inventor has finished the present invention by concentrating on studies.

An object of the present invention is to provide a kind of Hetergeneous product of bio-active protein.

Another object of the present invention provides the preparation method of the non-homogeneous goods of above-mentioned biological activity protein.

Of the present invention also have a purpose to provide the pharmaceutical composition that contains the non-homogeneous goods of above-mentioned biological activity protein.

It is the G-CSF (PEG-GCSF) that 20000 daltonian 2-methoxy methyl imido grpup methyl polyoxyethylene glycol chemistry are modified by molecular weight that the non-homogeneous goods of biological activity protein provided by the present invention comprise 15%-85%, and 85%-15%G-CSF.

Goods of the present invention are preferably and comprise 35%-80%PEG-GCSF and 65%-20%G-CSF; Be more preferred from and comprise 70%PEG-GCSF and 30%G-CSF.

The preparation method of the non-homogeneous goods of biological activity protein provided by the present invention may further comprise the steps:

(1) under alkaline environment, make G-CSF and peg molecule (2-methoxy methyl imido grpup methyl polyoxyethylene glycol) that coupled reaction take place; With

(2) remove remaining polyoxyethylene glycol.

Among the preparation method of the present invention, described alkaline environment is meant pH8.0; Described temperature of reaction is 4-25 ℃; The described reaction times is 5-40 hour.The removal of remaining 2-methoxy methyl imido grpup methyl polyoxyethylene glycol can be adopted method well known to those skilled in the art.

The non-homogeneous goods of biological activity protein of the inventive method preparation can form pharmaceutical composition with pharmaceutically acceptable additive.Described pharmaceutical composition comprises G-CSF and the G-CSF and the pharmaceutically acceptable additive of the 2-methoxy methyl imido grpup methyl polyoxyethylene glycol chemistry modification of significant quantity.

Described pharmaceutical composition is the physical condition stable formulation.It can be injection or oral preparations.Additive in the described preparation comprises thinner, buffer reagent, solubilizing agent, lubricant, emulsifying agent, suspending agent, sequestrant, antioxidant, sanitas, isotonic regulator, weighting agent and/or protective material.

Described thinner can be water, ethanol, propylene glycol, glycerine etc.Described buffer reagent is such as acetate, phosphoric acid salt, carbonate etc.Described emulsifying agent is a polysorbate etc.Described suspending agent is such as gelatin, glycine etc.Described sequestrant is such as EDTA-2Na.Described antioxidant is such as S-WAT, Sodium Pyrosulfite, xitix, vitamin-E etc.Described sanitas is a phenylcarbinol etc.Described isotonic regulator is such as sodium-chlor, glucose.Described weighting agent is N.F,USP MANNITOL, glycine, lactose etc.Described protective material is lactose, sucrose etc.

Above-described preparation method of the present invention can be coupled to activated polyglycol on the proteinic amino-acid residue, makes protein macromoleculeization.Owing to selected to have the 2-methoxy methyl imido grpup methyl polyoxyethylene glycol of the molecular weight of 20000Da, and by the control reaction conditions, as select suitable damping fluid and pH value, obtain having the PEG-GCSF and the G-CSF mixed preparation of certain proportioning, the best of PEG-GCSF and G-CSF ratio is 7: 3 in the products therefrom.Said preparation is rapid-action, acts on the length of holding time, stabilized aqueous solution.It has the advantage of PEG-GCSF and G-CSF concurrently, and has avoided deficiencies of they both independent uses effectively.Its onset time is shorter than pure PEG-GCSF, and biological half-life is longer than pure G-CSF.

Simultaneously, production technique of the present invention is simple, only promptly finishes combining of PEG and GCSF with a step chemical reaction, and has saved the loaded down with trivial details step of the single pure product of later separation, greatly reduces production cost, more helps large-scale industrialized production.

Description of drawings

Fig. 1 is the outflow situation of PEG-GCSF and G-CSF mixed product process molecular sieve chromatography.

Fig. 2 is the SDS-PAGE collection of illustrative plates of PEG-GCSF and G-CSF mixed product.

Fig. 3 is the size-exclusion HPLC collection of illustrative plates of PEG-GCSF and G-CSF mixed product.

Fig. 4 is the isoelectric focusing electrophoresis collection of illustrative plates of PEG-GCSF and G-CSF mixed product.

Embodiment

The invention will be further described below to use embodiment and experimental example, and they are intended to set forth optimum implementation of the present invention.Those skilled in the art are according to enlightenment of the present invention, and the various changes in conjunction with the general knowledge of this area is done all drop in the scope of the application's claim.

Example one

1. recombinant human g-csf's preparation

The aminoacid sequence of human G-CSF is as follows:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys

Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu

Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu

Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly

Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu

Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu

Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly

Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu

Arg His Leu Ala Gln Pro

The present inventor will be contained the plasmid of this sequence, and transformed into escherichia coli is expressed, and the tropina that obtains is carried out renaturation, and (referring to direction east etc., the Chinese biological goods are learned magazine, 1997,10 (1): 1-4 through ion-exchange, molecular sieve column purifying; And U.S. Pat P4,810,643), obtain the G-CSF work in-process, as the raw material of Pegylation.

2. specimen preparation

(1) G-CSF of polyoxyethylene glycol chemistry modification and the preparation of G-CSF mixed product

With the as above 1.5mg/ml G-CSF solution of preparation in 1, sodium phosphate buffer dialysed overnight with 100mM (pH8.0), (mol ratio is polyoxyethylene glycol: G-CSF=5: 1), slowly stirred 10 hours in 4 ℃ to add the molecular-weight average be dissolved in this damping fluid and be 20000 2-methoxy methyl imido grpup methyl polyoxyethylene glycol.

To carry out sieve chromatography with the protein that aforesaid method obtains, to remove unreacted polyoxyethylene glycol.Post is Pharmacia Sephcryl S-200HR, 300ml.With 20mM sodium-acetate (pH4.0) damping fluid balance.Last sample albumen in the proteic outflow situation of 280nm place monitoring, merges the target protein peak with 6ml/ minute flow velocity wash-out 200 minutes, the results are shown in Figure 1.

(2) preparation of reference substance PEG-GCSF (pure product)

G-CSF solution with 2mg/ml, sodium phosphate buffer dialysed overnight with 100mM (pH8.0), (mol ratio is polyoxyethylene glycol: G-CSF=5: 1), slowly stirred 12 hours in 4 ℃ to add the molecular-weight average be dissolved in this damping fluid and be 20000 2-methoxy methyl imido grpup methyl polyoxyethylene glycol.

Products therefrom 20mM sodium acetate (pH4.0) dialysed overnight.Be splined on Pharmacia CMSepharoseFF post (1ml resin-bonded 1mg protein) then, with buffer A (20mM sodium-acetate, pH4.0) balance columns.With sample on the protein, again with buffer B (sodium-chlor of 1M), its concentration gradient is that 0-30% carries out the concentration gradient wash-out.Flow velocity is 3ml/ minute, and elutriant is collected the part of protein content greater than 0.5mg/ml in the monitoring of 280nm place.The stream part that merges different peaks is carried out the assay products biological activity determination

To carry out sieve chromatography from the protein that ion exchange column obtains.Post is PharmaciaSephcryl S-200 HR, 300ml.With 20mM sodium-acetate (pH4.0) damping fluid balance.Last sample albumen in the proteic outflow situation of 280nm place monitoring, merges the target protein peak with 6ml/ minute flow velocity wash-out 200 minutes.Be purity and reach 99% pure PEG-GCSF.

3. molecular weight of product analysis

(1) SDS-PAGE electrophoresis

Utilize 10% sex change sds polyacrylamide gel electrophoresis, and use coomassie brilliant blue staining.The results are shown in accompanying drawing 2.Among the figure, the first hurdle display standard protein molecular weight; Second hurdle shows the molecular weight of PEG-GCSF and G-CSF mixed product; Third column is the molecular weight of the pure product of PEG-GCSF; The 4th hurdle is the molecular weight of the pure product of G-CSF.As seen from Figure 2, in the mixed product of PEG-GCSF and G-CSF, the molecular weight of PEG-GCSF is 38,800, and the molecular weight of G-CSF is 18,800.

(2) size-exclusion HPLC

Adopting TSK gel SW3000 gel column, is moving phase with 10mM sodium phosphate buffer (pH7.4), carries out size-exclusion HPLC, and flow velocity is 1.0ml/ minute, and elutriant is monitored at the 280nm place.The results are shown in Figure 3.From the size-exclusion HPLC collection of illustrative plates of non-homogeneous goods shown in Figure 3 as calculated machine peak area is carried out integrated, data are as follows:

Numbering	Time min	Title	Peak height uv	Peak height %	Area uv.sec	Area %	Concentration
								1	13.88	Unknown	51742	63.35	654049	69.99	0.000E+00
2	15.11	Unknown	29925	36.65	280393	30.01	0.000E+00
											81667	100.00	934442	100.00

Above result shows, PEG-GCSF: G-CSF=7 in PEG-GCSF and the G-CSF mixed product: 3.

4. product isoelectric point determination

Take from respectively system PEG-GCSF and G-CSF mixed preparation, the pure product of PEG-GCSF and the U.S. G-CSF of Amgen company standard substance in contrast liquid and each 2 μ l of iso-electric point reference liquid add respectively in the well of IEF glue, focus on.100V 15 minutes, 200V 15 minutes, 450V 60 minutes stops to focus on (this moment, electric current went to zero).Then, fix and decolour, the results are shown in Figure 4.What first hurdle showed among Fig. 4 is the GCSF sample; What second hurdle showed is the pure product of PEG-GCSF; What third column showed is the mixed product of PEG-GCSF and G-CSF.From Fig. 4 as seen, the pure product of sample P EG-GCSF and G-CSF standard substance and self-control PEG-GCSF and G-CSF mixed product all have identical iso-electric point.

5. product stability research

Place 37 ℃ to place 48 days the injection liquid of PEG-GCSF and G-CSF,, measure the external biological activity respectively at the 0th day, the 6th day, the 12nd day, the 24th day, the 36th day and sampling in the 48th day.The results are shown in Table 1.

The stability of the PEG-GCSF of table 1 different time and G-CSF mixed product

Time	The NFS-60 method records relative reactivity
		0 day	100％
6 days	98.1％
		12 days	97.6％
24 days	97.2％
		36 days	97.4％
48 days	96.5％

From the result of table 1 as can be seen, PEG-GCSF and G-CSF do not reduce basically placing 48 days artifact activity, prove that its character is highly stable.

6. external biological determination of activity

The cell strain NFS-60 that utilization relies on G-CSF is containing 10% in the IMDM of heat-inactivated foetal calf serum and G-CSF substratum, in 37 ℃, 5%CO ₂Cultivated 72 hours.Then, substratum with no G-CSF cleans cell 2 times, add 96 orifice plates with 10,000 cells in every hole/50 μ l, and add respectively that concentration with IMDM-FBS preparation is 20,40,80,160, the U.S.'s G-CSF of Amgen company standard substance and the self-control PEG-GCSF sample of 320pg/ml.In 37 ℃, 5%CO ₂Cultivate after 48 hours, press the explanation in the heterotope detection kit of Cell Titer96 Aqueous cell growth, add freshly prepared 20: the 1 blended MTS/PMS solution of pressing, 20 μ l/ holes, continue to cultivate 4 hours, read the value of 490nm with the BioTek microplate reader.The software that carries on the microplate reader can demonstrate typical curve and calculate the biological activity of testing sample.The results are shown in Table 2.

The determination of activity of table 2 external biological

Sample	Concentration	OD490nm
			G-CSF	0pg/ml	0.086
20pg/ml	0.174
		40pg/ml		0.335
60pg/ml	0.521
		80pg/ml		0.690
160pg/ml	1.321

	320pg/ml	2.750
			PEG-GCSF	100pg/ml	0.439
PEG-GCSF and G-CSF mixed product	100pg/ml	0.673

As shown in table 2, PEG-GCSF that employing the inventive method prepares and the mixed product of G-CSF have the effect that obvious in-vitro is induced the neutrophilic granulocyte fast breeding, and its activity is higher than pure PEG-GCSF about 50%.Compare with the PEG-GCSF in the European patent EP 0335423, high especially about 10 times.

7. biological activity determination in the body

Select ICR mouse (18-22 gram), make PEG-GCSF and G-CSF injection liquid by oneself with 10 μ g protein/kg body weight metering intravenous injection, and with the U.S.'s G-CSF of Amgen company standard substance as positive control.After the injection, certain hour is got peripheral blood at interval, and neutrophilic granulocyte is counted.The results are shown in Table 3.

Biological activity determination in table 3 body

	Leukocyte count (10 9/L)
								0.5 hour	6 hours	20 hours	24 hours	30 hours	48 hours	72 hours
	G-CSF	18±3.9	71±4.8	21±4.6	19±5.9	18±4.3	18±3.7								18±4.1
PEG-GCSF								17±3.1	40±7.4	75±8.3	104±6.2	110±5.9	71±6.7	19±5.4
	PEG-GCSF and G-CSF mixed product	17±4.4	60±5.5	90±7.1	100±6.3	95±6.7	65±5.1								19±4.2

Shown in table 3 result, the PEG-GCSF and the G-CSF mixed product that adopt method of the present invention to make still have biologic activity in vivo, and the GCSF that contrast biological half-life has prolonged nearly 3 times.Compare with the PEG-GCSF in the European patent EP 0401384, product of the present invention prolongs about 5 hours biological half-life.

8. Plasma Concentration and time relation

Select ICR mouse (18-22 gram), with 10 μ g protein/kg body weight metering subcutaneous injection self-control PEG-GCSF and G-CSF mixed product injection liquid (PEG-GCSF accounts for 70%), and with the pure product of PEG-GCSF in contrast.After the injection, the interval certain hour, it is stand-by to get peripheral blood.

The concentration that will be made into IMDM-FBS is 20,40,80,160, the U.S.'s G-CSF of Amgen company standard substance of 320pg/ml and the blood sample of above preparation add in 96 well culture plates, each concentration 3 hole, and every hole 100 μ l put into incubator (5%CO then ₂, 100% humidity, 37 ℃) and pre-warm 30 minutes, NFS-60 cell strain Hank ' the s liquid that will go down to posterity therebetween after cultivating is washed 3 times, each 1500rpm; 5 minutes, supernatant liquor was removed in centrifugal back, adds 10%IMDM-FBS and makes 5 * 10 ⁵/ ml cell concn adds in above 96 well culture plates, and every hole 50 μ l put into incubator (5%CO ₂, 100% humidity, 37 ℃ ± 1 ℃) cultivated 21 hours.After 21 hours, every hole adds ³H-thymidine (5 μ ci/ml) 50 μ l continue to cultivate 6 hours, after the end, and collecting cell.65 ℃ of dryings were counted 1 minute on the bright calculating instrument of liquid then.The results are shown in Table 4.

The Plasma Concentration of table 4 PEG-GCSF and G-CSF mixed product and time relation

	Pitch time	PEG-GCSF	PEG-GCSF and G-CSF mixed product
				Plasma Concentration (u/ml blood)	10 minutes	4.15×10 5	1.61×10 6
20 minutes	7.74×10 5	3.78×10 6
			40 minutes		1.80×10 6	8.24×10 6
80 minutes	4.52×10 6	2.13×10 7
			2 hours		1.02×10 7	1.74×10 7
5 hours	1.86×10 7	9.52×10 6
			10 hours		1.10×10 7	3.65×10 6
16 hours	7.56×10 6	2.88×10 6
			24 hours		2.01×10 6	5.24×10 5

As can be seen from Table 4, the onset of PEG-GCSF and G-CSF mixed product is faster more than 30 minutes than control group.In addition, mixed preparation of the present invention is compared fast approximately 30 minutes of onset with PEG-GCSF in the European patent EP 0335423.

9. acute toxicity test

Get 20 of Kunming mouses, body weight 18.1 ± 0.8 grams, male and female half and half, fasting was tried after 12 hours.With 3600 μ g protein/kg body weight metering intravenous injection self-control PEG-GCSF and G-CSF mixed preparation injection liquid, observe reaction and the death condition in 7 days after its administration, the results are shown in Table 5.

The determination of acute toxicity of table 5 mixed product

		PEG-GCSF and G-CSF mixed preparation		Mean body weight (gram)	Blank		Mean body weight (gram)
								Male	Female	Male	Female
		The dead mouse number	1 day		0	0						19.0±0.8	0	0	19.1±0.9
2 days	0			0			20.2±1.0	0	0	20.2±0.8
			3 days		0	0					21.4±1.0	0	0	21.5±0.9
4 days	0			0			22.3±1.5	0	0	22.6±1.4
			5 days		0	0					23.0±1.4	0	0	23.3±1.3
6 days	0			0			23.8±1.5	0	0	24.1±1.5
			7 days		0	0					24.7±1.6	0	0	24.9±1.5
Mortality ratio %				0			0		0	0
		LD50			＞3600μg/kg						＞3600μg/kg
Active situation				Normally			Normally		Normally	Normally

Example two

With 1.5mg/ml G-CSF solution, sodium phosphate buffer dialysed overnight with 100mM (pH 8.0), (mol ratio is polyoxyethylene glycol: G-CSF=1: 1), 25 ℃ were slowly stirred 5 hours to add the molecular-weight average be dissolved in this damping fluid and be 20000 2-methoxy methyl imido grpup methyl polyoxyethylene glycol.

To carry out sieve chromatography with the protein that aforesaid method obtains, to remove unreacted polyoxyethylene glycol.Post is Pharmacia SepHcryl S-200 HR, 300ml.With 20mm sodium-acetate (pH4.0) damping fluid balance.Last sample albumen in the proteic outflow situation of 280nm place monitoring, merges the target protein peak with 6ml/ minute flow velocity wash-out 200 minutes.Product is through HPLC assay PEG-GCSF: G-CSF=15: 85.The external biological determination of activity the results are shown in Table 4.

Example three

With 1mg/ml G-CSF solution, sodium phosphate buffer dialysed overnight with 100mM (pH8.0), (mol ratio is polyoxyethylene glycol: G-CSF=6: 1), 4 ℃ were slowly stirred 40 hours to add the molecular-weight average be dissolved in this damping fluid and be 20000 2-methoxy methyl imido grpup methyl polyoxyethylene glycol.

To carry out sieve chromatography with the protein that aforesaid method obtains, to remove unreacted polyoxyethylene glycol.Post is Pharmacia SepHcryl S-200 HR, 300ml.With 20mm sodium-acetate (pH4.0) damping fluid balance.Last sample albumen in the proteic outflow situation of 280nm place monitoring, merges the target protein peak with 6ml/ minute flow velocity wash-out 200 minutes.Product is through HPLC assay PEG-GCSF: G-CSF=85: 15.The external biological determination of activity the results are shown in Table 6.

The external biological specific activity of the PEG-GCSF of the different proportionings of table 6 and G-CSF mixed product

Sample	PEG-GCSF content	The NFS-60 method records relative reactivity
			G-CSF	0％	100％
PEG-GCSF and G-CSF	85％	87％
			PEG-GCSF and G-CSF	70％	78％
PEG-GCSF and G-CSF	50％	63％
			PEG-GCSF and G-CSF	15％	55％
PEG-GCSF	100％	50％

Example four

Get the sodium-acetate buffer 650ml that the pharmaceutical grade sodium-acetate is mixed with 10mM (pH4.0).Taking by weighing pharmaceutical grade auxiliary material N.F,USP MANNITOL 50 grams is dissolved in the above-mentioned sodium-acetate buffer.Accurately get PEG-GCSF and G-CSF mixed product 300mg,, be settled to 1000ml with above-mentioned solution mixing.This solution is with 0.22 μ m membrane filtration, and aseptic subpackaged, every bottle of 1ml, tamponade, Zha Gai promptly obtain the injection injection of 300 μ g/ bottles.

Claims (7)

1. Hetergeneous product of bio-active protein, wherein comprising 15%-85% is the chemical people's who modifies of 20000 daltonian 2-methoxy methyl imido grpup methyl polyoxyethylene glycol granulocyte colony-stimulating factor and 85%-15% people's granulocyte colony-stimulating factor by molecular weight.

2. goods according to claim 1, wherein comprising 70% is the people's that modifies of 20000 daltonian 2-methoxy methyl imido grpup methyl polyoxyethylene glycol chemistry granulocyte colony-stimulating factor and 30% people's granulocyte colony-stimulating factor by molecular weight.

3. the preparation method of claim 1 or 2 described goods is characterized in that may further comprise the steps:

(1) under the temperature of the alkaline environment of pH8.0 and 4-25 ℃, making people's granulocyte colony-stimulating factor and molecular weight is 20000 daltonian 2-methoxy methyl imido grpup methyl peg molecule generation coupled reactions; With

(2) remove remaining 2-methoxy methyl imido grpup methyl polyoxyethylene glycol.

4. preparation method as claimed in claim 3, wherein the reaction times is 5-40 hour.

5. preparation method as claimed in claim 3, wherein the mol ratio of 2-methoxy methyl imido grpup methyl polyoxyethylene glycol and people's granulocyte colony-stimulating factor is 5: 1 in this step (1).

6. the pharmaceutical composition of the described goods of claim 1, what comprise significant quantity is the chemical people's who modifies of 20000 daltonian 2-methoxy methyl imido grpup methyl polyoxyethylene glycol granulocyte colony-stimulating factor and people's granulocyte colony-stimulating factor by molecular weight, with pharmaceutically acceptable additive.

7. pharmaceutical composition as claimed in claim 6, wherein said additive comprises thinner, buffer reagent, solubilizing agent, lubricant, emulsifying agent, suspending agent, sequestrant, antioxidant, sanitas, isotonic regulator, weighting agent and/or protective material.

Images